Download PDF
Nuklearmedizin 1984; 23(03): 111-118
DOI: 10.1055/s-0038-1624203
Originalarbeiten – Original Articles
Schattauer GmbH

Recent Developments in the Field of 123I-Radiopharmaceuticals [*]

Neuere Entwicklungen auf dem Gebiet der 123J-markierten Radiopharmazeutika
H.-J. Machulla
1   From the Institut für Medizinische Strahlenphysik und Strahlenbiologie, Universitätsklinikum Essen, Essen, Federal Republic of Germany
,
E. J. Knust
1   From the Institut für Medizinische Strahlenphysik und Strahlenbiologie, Universitätsklinikum Essen, Essen, Federal Republic of Germany
› Author AffiliationsWe are gratefully indebted to Prof. Dr. C. Streffer and Prof. Dr. J. Rassow for their generous support and continuously encouraging interest throughout the entire project.
Further Information

Publication History

Received: 15 March 1984

Publication Date:
10 January 2018 (online)

    Permissions and Reprints

Summary

Due to its advantageous nuclear physical properties iodine-123 is an excellent label for radiopharmaceuticals very well suited for measurements by γ-cameras and single-photon emission tomography. The development of 123I-radiopharmaceuticals should be based on a clear biochemical concept, reliable labelling procedures and careful pharmacokinetic studies in order to evaluate the physiological behaviour of the radioiodinated compounds being analogues of metabolic substrates. The development of 123I-labelled fatty acids and biogenic amines clearly proved the successful use of 123I for labelling compounds applied in medical diagnosis.

Zusammenfassung

Aufgrund seiner hervorragenden kernphysikalischen Eigenschaften stellt 123J ein ausgezeichnetes Radionuklid zur Markierung von Radiopharmaka dar, die somit sehr gut geeignet sind für Messungen mit herkömmlichen γ-Kameras oder mittels der Single Photon Emission Tomography (SPECT). Voraussetzung für die Entwicklung von 123J-Radiopharmaka sind klare biochemische Konzepte, zuverlässige Markierungsmethoden und pharmakokinetische Studien zur Ermittlung des physiologischen Verhaltens radiojodierter Verbindungen als Analoga metabolischer Substrate. Die Entwicklung 123J-markierter Fettsäuren und biogener Amine beweist sehr deutlich die erfolgreiche Verwendungsmöglichkeit von 123J zur Markierung von Verbindungen für die Anwendung in der nuklear-medizinischen Diagnose.

* 3rd International Symposium on Radiopharmacology, Freiburg i.Br., September 1983.


 

  • References

  • 1 Dudczak R, Kletter K, Frischauf H, Schmoliner R, Derfler K, Losert U. Myocardial turnover rates of (123I)-heptadecanoic acid and p-(123I-phenyl)-pentadecanoic acid. In Radioaktive Isotope in Klinik und Forschung, Band 15, 2. Teil. 1982. Höfer R. Hrsg.) 685-96 Egermann, Wien:
    Google Scholar
  • 2 Dudczak R. Myokardszintigraphie mit 123J-markierten Fettsäuren. Wien. klin. Wschr. 1983; 95 (Suppl. 143) 1-35.
    PubMedGoogle Scholar
  • 3 Eisenhut M. Simple labelling of ωphenylfatty acids by iodine isotope exchange. Int. J. appl. Radiat. Isot. 1982; 33: 499-504.
    CrossrefPubMedGoogle Scholar
  • 4 Elmaleh D. R., Knapp F. F., Yasuda T, Coffey J. L., Kopiwoda S, Okada R, Strauss H. W. Myocardial imaging with 9-(123mTe)-tellurahep-tadecanoic acid. J. nucl. Med. 1981; 22: 994-9.
    PubMedGoogle Scholar
  • 5 Feinendegen L. E., Vyska K, Freundlieb C. h.r, Höck A, Machulla H-J, Kloster G, Stöcklin G. Non-invasive analysis of metabolic reactions in body tissues. The case of myocardial fatty acids. Eur. J. nucl. Med. 1981; 6: 191-200.
    CrossrefPubMedGoogle Scholar
  • 6 Franke L, Hanson R, Lee S. H., Seitz D. Radiohalodestannylation Labelling of substituted trialkylstannylarenes and ethylenes. J. nucl. Med. 1983; 24: 116.
    PubMedGoogle Scholar
  • 7 Freundlieb C, Höck A, Vyska K, Feinendegen L. E., Machulla H-J, Stöcklin G. Myocardial imaging and metabolic studies with 17-l23I-heptadecanoic acid. J. nucl. Med. 1980; 21: 1043-50.
    PubMedGoogle Scholar
  • 8 Goodman M. M., Knapp Jr F. F., Callahan A. P., Ferren L. A. Synthesis and biological evaluation of 17-(131I)-iodo-9telluraheptadecanoic acid A potential myocardial imaging agent. J. med. Chem. 1982; 25: 613-8.
    CrossrefPubMedGoogle Scholar
  • 9 Goodman M. M., Knapp Jr F. F., Callahan A. P., Ferren L. A. A new wellretained myocardial imaging agen. Radioiodinated 15-(p-iodophenyl)-6tellurapentadecanoic acid. J. nucl. Med. 1982; 23: 904-8.
    PubMedGoogle Scholar
  • 10 Goodman M. M., Cunningham E. B., Callahan A. P., Kirsch G, Knapp Jr F. F. Synthesis and evaluation of radioiodinated terminal p-iodophenyl-substituted aand ß-methyl-branched fatty acids: A new class of myocardial imaging agents. J. med. Chem. (submitted).
    Google Scholar
  • 11 Hill T. C., Holman B. L., Lovett R, O’Leary D. H., Front D, Magistretti P, Zimmerman R. E., Moore S, Clouse M. E., Wu J. L., Lin T. H., Baldwin R. M. Initial experience with SPECT (single photon computerized tomography) of the brain using N-isopropyl-123I-p-iodoamphetamine. J. nucl. Med. 1982; 23: 191-5.
    PubMedGoogle Scholar
  • 12 Höck A, Freundlieb C, Vyska K, Lösse B, Erbel R, Feinendegen L. E. Myocardial imaging and metabolic studies with 17-123I-heptadecanoic acid in patients with idiopathic congestive cardiomyopathy. J. nucl. Med. 1983; 24: 22-8.
    PubMedGoogle Scholar
  • 13 Holman B. L., Zimmerman R. E., Schapiro J. R., Kaplan M. L., Jones A. G., Hill T. C. Biodistribution and dosimetry of N-isopropyl-p-(123I)-iodoamphetamine in the primate. J. nucl. Med. 1983; 24: 922-31.
    PubMedGoogle Scholar
  • 14 Kabalka G. W., Gooch E. E., Sastry K. A.R. Rapid and mild syntheses of radioiodine-labeled radiopharmaceuticals. J. nucl. Med. 1981; 22: 908-12.
    PubMedGoogle Scholar
  • 15 Knapp Jr F. F., Ambrose K. R., Callahan A. P., Ferren L. A., Grigsby R. A., Irgolic K. J. Effects of chain length and tellurium position on the myocardial uptake of 123mTe fatty acids. J. nucl. Med. 1981; 22: 988-93.
    PubMedGoogle Scholar
  • 16 Knapp Jr F. F., Goodman M. M., Callahan A. P. Radioiodination of 15-(piodophenyl)-6-tellurapentadecanoic acid by triazene decomposition with radioiodide. J. lab. Comp. Radiopharm. (in press).
    Google Scholar
  • 17 Kuhl D. E., Barrio J. R., Huang S. C., Selin C, Ackermann R. F., Lear J. L., Wu J. L., Lin T. H., Phelps M. E. Quantifying local cerebral blood flow by N-isopropyl-p-(‘23I)-iodoamphetamine (IMP) tomography. J. nucl. Med. 1982; 23: 196-203.
    PubMedGoogle Scholar
  • 18 Kulkarni P. V., Parkey R. W. Radioiodination of phenylpentadecanoic acid via an organothallium intermediate. J. lab. Comp. Radiopharm. (in press).
    Google Scholar
  • 19 Kung H. F., Blau M. Regional in tracellular pH shift. A proposed new mechanism for radiopharmaceutical uptake in brain and other tissues. J. nucl. Med. 1980; 21: 147-52.
    PubMedGoogle Scholar
  • 20 Kung H. F., Tramposch K. M., Blau M. A new brain perfusion imaging agent: (123I) HIPDM. N,N,N’-trimethylN’-(2-hydroxy-3-methyl-5-iodobenzyl)l,3propanediamine. J. nucl. Med. 1983; 24: 66-72.
    PubMedGoogle Scholar
  • 21 Lassen N. A., Henriksen L, Holm S, Barry D. I., Paulson O. B., Vorstrup S, Rapin J, le Poncin-Lafitte M, Moretti J. L., Askienazy S, Raynaud C. Cerebral blood-flow tomography. 133Xenon compared with N-isopropyl-amphetamine123iodine. J. nucl. Med. 1983; 24: 17-21.
    PubMedGoogle Scholar
  • 22 Livni E, Elmaleh D. R., Levy S, Brownell G. L., Strauss H. W. Beta-methyll-nC-heptadecanoic acid. A new myocardial metabolic tracer for positron emission tomography. J. nucl. Med. 1982; 23: 169-75.
    PubMedGoogle Scholar
  • 23 Machulla H-J, Läufer P, Stöcklin G. Radioanalytical quality control of UC-, 18Fand 123I-labelled compounds and radiopharmaceuticals. J. radioanal. Chem. 1976; 32: 381-400.
    CrossrefGoogle Scholar
  • 24 Machulla H-J, Stöcklin G, Kupfernagel Ch., Freundlieb Ch., Höck A, Vyska K, Feinendegen L. E. Comparative evaluation of fatty acids labelled with nC, 34mCl, 77Br and 123I for metabolic studies of the myocardium. J. nucl. Med. 1978. 19 298-302.
    Google Scholar
  • 25 Machulla H-J, Stöcklin G, Kupfernagel Ch., Vyska K, Höck A, Freundlieb C. h.r, Feinendegen L. E. Comparative studies of different labelled fatty acids for heart muscle metabolism. In Nuklearmedizin. 1978. Woldring M, Schmidt A. E. H. Hrsg.), S. 212-5 Schattauer, Stuttgart New York:
    Google Scholar
  • 26 Machulla H-J, Marsmann M, Dutschka K. Biochemical concept and synthesis of a radioiodinated phenylfatty acid for in vivo metabolic studies of the myocardium. Eur. J. nucl. Med. 1980; 5: 171-3.
    CrossrefPubMedGoogle Scholar
  • 27 Machulla H-J, Marsmann M, Dutschka K. Radiopharmaceuticals. I. Synthesis of radioiodinated phenylfatty acids for studying myocardial metabolism. J. radioanal. Chem. 1980; 56: 253-61.
    CrossrefGoogle Scholar
  • 28 Machulla H-J, Marsmann M, Dutschka K, van Beuningen D. Radiopharmaceuticals. II. Radiobromination of phenylpentadecanoic acid and biodistribution in mice. Radiochem. radioanal. Letters. 1980; 42: 243-50.
    Google Scholar
  • 29 Machulla H-J, Dutschka K, van Beuningen D, Chen T. Development of 15-(p-l23I-phenyl)-pentadecanoic acid for in vivo diagnosis of the myocardium. J. radioanal. Chem. 1981; 65: 279-86.
    CrossrefGoogle Scholar
  • 30 Machulla H-J, Dutschka K. Iodination methods for routine preparation of 17-123I-heptadecanoic acid and 15-(p-123Iphenyl)-pentadecanoic acid. J. radioanal. Chem. 1981; 65: 123-30.
    CrossrefGoogle Scholar
  • 31 Machulla H-J, Chen T, Knust E. J., Dutschka K, Meissner P, Scharf-Bornhofen E, Blümchen G. 15-(p-123I-phenyl)pentadecanoic acid as an indicator for myocardial metabolism. In Nuclear Medicine and Biology. 1982. Raynaud C. Ed.) Vol. II, 1385-9 Pergamon Press; Paris:
    Google Scholar
  • 32 Machulla H-J. Radioactive labeling of fatty acids for metabolic studies. In Applications of Nuclear and Radiochemistry. 1982. Lambrecht R. M., Morcos N. Eds.) 325-41. Pergamon Press; New York:
    Google Scholar
  • 33 Machulla H-J, Knust E. J., Baldwin R. M., Schmidt U, Dutschka K, Molls M. Radiopharmaceuticals. VI. Nisopropyl-p-123I-amphetamine, accumulation and elimination in mice. Radiochem. radioanal. Letters. 1983; 57: 241-6.
    Google Scholar
  • 34 Reske S. N., Biersack H. J., Lackner K, Machulla H-J, Knopp R, Hahn N, Winkler C. Assessment of regional myocardial uptake and metabolism of co-(p123I-phenyl)-pentadecanoic acid with serial single-photon emission tomography. Nucl. Med. 1982; 20: 249-53.
    Google Scholar
  • 35 Reske S. N. 123I-Phenyl-Pentadecansäure Ein neuer Tracer zur Untersuchung des myokardialen Metabolismus freier Fettsäuren. Der Nuklearmediziner. 1983; 1: 25-16.
    Google Scholar
  • 36 Reske S. N., Schmitz B, Machulla H-J, Sauer W, Knust E. J., Egge H, Winkler C. Myocardial metabolism of 15-(pI23I-phenyl)-pentadecanoic acid compared to l-14C-palmitic acid. In Radioaktive Isotope in Klinik und Forschung, Band 16, 2. Teil. 1984. Höfer R. Hrsg.), S. 367-73 Egermann, Wien:
    Google Scholar
  • 37 Schweickert R. Private Mitteilung. Kemforschungszentrum Karlsruhe, Sept. 1983
    PubMedGoogle Scholar
  • 38 Van der Wall E. E., Heidendal G. A.K, den Hollander W, Westera G, Roos J. P. 123I labeled hexadecanoic âcid in comparison with “‘thallium for myocardial imaging in coronary heart disease. A preliminary study. Eur. J. nucl. Med. 1980; 5: 401-5.
    CrossrefPubMedGoogle Scholar
  • 39 Van der Wall E. E., den Hollander W, Heidendal G. A. K., Westera G, Majid P. A., Roos J. P. Dynamic myocardial scintigraphy with 123I-labeled free fatty acids in patients with myocardial infarction. Eur. J. nucl. Med. 1981; 6: 383-9.
    CrossrefPubMedGoogle Scholar
  • 40 Van d. e.r, Wall E. E., Heidendal G. A.K, den Hollander W, Westera G, Roos J. P. Metabolic myocardial imaging with 123I-labeled heptadecanoic acid in patients with angina pectoris. Eur. J. nucl. Med. 1981; 6: 391-6.
    CrossrefPubMedGoogle Scholar
  • 41 Vyska K, Freundlieb C, Höck A, Feinendegen L. E., Machulla H-J, Stöcklin G. Myocardial imaging and measurement of myocardial fatty acid metabolism using (o-l23I-heptadecanoic acid. Adv. Clin. Cardiol. 1980; 1: 422-36.
    Google Scholar
  • 42 Weinreich R. Critical comparison of production methods for 123I. In 123I in Western Europe. 1976. Qaim S. M., Stöcklin G, Weinreich R. Eds.) 49-69. JülConf-20, August.
    Google Scholar
  • 43 Winchell H. S., Horst W. D., Braun L. H., Oldendorf W. H., Hattner R, Parker H. N-Isopropyl-(l23I)-p-iodoamphetamine. Single-pass brain uptake and washout; binding to brain synaptosomes; and localization in dog and monkey brain. J. nucl. Med. 1980; 21: 947-52.
    PubMedGoogle Scholar
  • 44 Winchell H. S., Baldwin R. M., Lin T. H. Development of 123I-labeled a mines for brain studies. Localization of l23Iiodophenylalkyl amines in rat brain. J. nucl. Med. 1980; 21: 940-6.
    PubMedGoogle Scholar